Ryan Shickman1,2, Jessica Famula1,2, Flora Tassone1,3, Maureen Leehey4, Emilio Ferrer1,5, Susan M Rivera1,5,6, David Hessl1,2. 1. MIND Institute, University of California Davis Medical Center, Sacramento, California, USA. 2. Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, California, USA. 3. Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Davis, California, USA. 4. Department of Neurology, University of Colorado, Denver, Colorado, USA. 5. Department of Psychology, University of California Davis, Davis, California, USA. 6. Center for Mind and Brain, University of California Davis, Davis, California, USA.
Abstract
BACKGROUND: Fragile X premutation carriers are at increased risk for fragile X-associated tremor ataxia syndrome (FXTAS), but to date we know little about prediction of onset and rate of progression and even less about treatment of this neurodegenerative disease. Thus, the longitudinal study of carriers, and the identification of potential biomarkers and prodromal states, is essential. Here we present results of baseline assessments from an ongoing longitudinal project. METHODS: The cohort consisted of 73 men, 48 with the fragile X mental retardation 1 (FMR1) premutation (55-200 cytosine-cytosine-guanine or CGG repeats) and 25 well-matched controls (< 40 repeats) aged between 40 and 75 years. At enrollment, none met criteria for FXTAS or had any clinically significant tremor or ataxia by blinded neurological examination. The battery consisted of measures of visual memory, spatial working memory, response inhibition, motor speed and control, planning and problem solving, sustained attention, and a standardized movement disorder evaluation. RESULTS: Contrary to expectations, there were no significant differences between premutation carriers and controls on any measure of executive function. However, the premutation carriers had significantly longer manual movement and reaction times than controls, and the significant interaction between CGG repeat and age revealed the slowest movement times among older carriers with higher CGG repeat alleles. A subset of premutation carriers had marginally lower scores on the ataxia evaluation, and they performed no differently from controls on the parkinsonism assessment. CONCLUSION: Early-developing cerebellar or fronto-motor tract white matter changes, previously documented in MRI studies, may underlie motor slowing that occurs before clinically observable neurological symptoms associated with FXTAS.
BACKGROUND:Fragile X premutation carriers are at increased risk for fragile X-associated tremorataxia syndrome (FXTAS), but to date we know little about prediction of onset and rate of progression and even less about treatment of this neurodegenerative disease. Thus, the longitudinal study of carriers, and the identification of potential biomarkers and prodromal states, is essential. Here we present results of baseline assessments from an ongoing longitudinal project. METHODS: The cohort consisted of 73 men, 48 with the fragile X mental retardation 1 (FMR1) premutation (55-200 cytosine-cytosine-guanine or CGG repeats) and 25 well-matched controls (< 40 repeats) aged between 40 and 75 years. At enrollment, none met criteria for FXTAS or had any clinically significant tremor or ataxia by blinded neurological examination. The battery consisted of measures of visual memory, spatial working memory, response inhibition, motor speed and control, planning and problem solving, sustained attention, and a standardized movement disorder evaluation. RESULTS: Contrary to expectations, there were no significant differences between premutation carriers and controls on any measure of executive function. However, the premutation carriers had significantly longer manual movement and reaction times than controls, and the significant interaction between CGG repeat and age revealed the slowest movement times among older carriers with higher CGG repeat alleles. A subset of premutation carriers had marginally lower scores on the ataxia evaluation, and they performed no differently from controls on the parkinsonism assessment. CONCLUSION: Early-developing cerebellar or fronto-motor tract white matter changes, previously documented in MRI studies, may underlie motor slowing that occurs before clinically observable neurological symptoms associated with FXTAS.
Authors: Jim Grigsby; Angela G Brega; Sébastien Jacquemont; Danuta Z Loesch; Maureen A Leehey; Glenn K Goodrich; Randi J Hagerman; Jennifer Epstein; Rebecca Wilson; Jennifer B Cogswell; Tristan Jardini; Flora Tassone; Paul J Hagerman Journal: J Neurol Sci Date: 2006-06-15 Impact factor: 3.181
Authors: David Hessl; John M Wang; Andrea Schneider; Kami Koldewyn; Lien Le; Christine Iwahashi; Katherine Cheung; Flora Tassone; Paul J Hagerman; Susan M Rivera Journal: Biol Psychiatry Date: 2011-07-23 Impact factor: 13.382
Authors: Philip O Buck; Ronald E Wilson; Lauren C Seeberger; Jill B Conner; Jane Castelli-Haley Journal: J Parkinsons Dis Date: 2011 Impact factor: 5.568
Authors: Jun Yi Wang; David Hessl; Andrea Schneider; Flora Tassone; Randi J Hagerman; Susan M Rivera Journal: JAMA Neurol Date: 2013-08 Impact factor: 18.302
Authors: Naomi J Goodrich-Hunsaker; Ling M Wong; Yingratana McLennan; Flora Tassone; Danielle Harvey; Susan M Rivera; Tony J Simon Journal: Front Hum Neurosci Date: 2011-07-14 Impact factor: 3.169
Authors: John M Wang; Kami Koldewyn; Ryu-Ichiro Hashimoto; Andrea Schneider; Lien Le; Flora Tassone; Katherine Cheung; Paul Hagerman; David Hessl; Susan M Rivera Journal: Front Hum Neurosci Date: 2012-10-30 Impact factor: 3.169
Authors: Joan A O'Keefe; Deborah Bang; Erin E Robertson; Alexandras Biskis; Bichun Ouyang; Yuanqing Liu; Gian Pal; Elizabeth Berry-Kravis; Deborah A Hall Journal: Mov Disord Clin Pract Date: 2020-08-29
Authors: Annie L Shelton; Jun Y Wang; Emily Fourie; Flora Tassone; Anna Chen; Lauren Frizzi; Randi J Hagerman; Emilio Ferrer; David Hessl; Susan M Rivera Journal: Front Neurosci Date: 2018-06-25 Impact factor: 4.677
Authors: Walker S McKinney; Zheng Wang; Shannon Kelly; Pravin Khemani; Su Lui; Stormi P White; Matthew W Mosconi Journal: Front Integr Neurosci Date: 2019-10-02
Authors: Jared J Schwartzer; Dolores Garcia-Arocena; Amanda Jamal; Ali Izadi; Rob Willemsen; Robert F Berman Journal: Front Neurosci Date: 2021-12-03 Impact factor: 4.677
Authors: Jinkuk Hong; Robert S Dembo; Leann Smith DaWalt; Murray Brilliant; Elizabeth M Berry-Kravis; Marsha Mailick Journal: SSM Popul Health Date: 2022-10-05
Authors: Jessica L Famula; Forrest McKenzie; Yingratana A McLennan; James Grigsby; Flora Tassone; David Hessl; Susan M Rivera; Veronica Martinez-Cerdeno; Randi J Hagerman Journal: Front Neurol Date: 2018-08-22 Impact factor: 4.003